Teicoplanin and alpha 1-antitrypsin are poorly studied drugs in the context of COVID-19, but they have shown positive results in severe COVID-19, as they have been reported to decrease the mortality rate and CRP concentration. The gene discussed is CRP; the disease is COVID-19.